Insights into the effects of diclofenac and other non-steroidal anti-inflammatory agents on ion channels

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 10, 2012, Pages 1359-1375

  Gwanyanya, Asfree ^a   MacIanskiene, Regina ^b   Mubagwa, Kanigula ^c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

diclofenac; ion channel; non steroidal anti inflammatory drug

Indexed keywords

ACETYLSALICYLIC ACID; ACID SENSING ION CHANNEL; CELECOXIB; DICLOFENAC; FENAMIC ACID DERIVATIVE; IBUPROFEN; INDOMETACIN; ION CHANNEL; LIGAND GATED ION CHANNEL; LIGAND GATED POTASSIUM ION CHANNEL; LUMIRACOXIB; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; NIFLUMIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PHENAZONE; POTASSIUM CHANNEL KCNQ2; POTASSIUM CHANNEL KCNQ3; POTASSIUM CHANNEL KV7; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; SHAB POTASSIUM CHANNEL; SHAKER POTASSIUM CHANNEL; SHAL POTASSIUM CHANNEL; TRANSIENT RECEPTOR POTENTIAL CHANNEL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED POTASSIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL;

ALZHEIMER DISEASE; ANALGESIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BRAIN EMBOLISM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHANNEL GATING; DIGESTIVE SYSTEM PERFORATION; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HUMAN; IC 50; INFLAMMATION; KIDNEY DISEASE; LIVER TOXICITY; LOW DRUG DOSE; NEOPLASM; NEPHROTOXICITY; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; POTASSIUM CURRENT; REVIEW; STOMACH ULCER; STRUCTURE ACTIVITY RELATION; THROMBOCYTE DYSFUNCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DICLOFENAC; DRUG DESIGN; DRUG INTERACTIONS; DRUG SYNERGISM; HUMANS; INFLAMMATION; ION CHANNELS; PAIN;

EID: 84865862836     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01479.x     Document Type: Review

References (128)

1. Vane JR,. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 232-235.
2. Botting RM,. Vane's discovery of the mechanism of action of aspirin changed our understanding of its clinical pharmacology. Pharmacol Rep 2010; 62: 518-525.
3. Vane JR, et al,. The mechanism of action of aspirin. Thromb Res 2003; 110: 255-258. (Pubitemid 37329821)
4. Hemler M, et al,. Purification of the cyclooxygenase that forms prostaglandins. Demonstration of two forms of iron in the holoenzyme. J Biol Chem 1976; 251: 5575-5579.
5. Xie WL, et al,. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A 1991; 88: 2692-2696.
6. Patrono C,. Aspirin: new cardiovascular uses for an old drug. Am J Med 2001; 110: 62S-65S. (Pubitemid 32144907)
7. Giovannucci E, et al,. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995; 333: 609-614.
8. Gupta RA, et al,. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001; 1: 11-21. (Pubitemid 33741877)
9. Pasinetti GM,. Cyclooxygenase and inflammation in Alzheimer's disease: experimental approaches and clinical interventions. J Neurosci Res 1998; 54: 1-6. (Pubitemid 28447183)
10. Subbaramaiah K, et al,. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 2003; 24: 96-102. (Pubitemid 36135884)
11. Liu H, et al,. Anticancer effect of celecoxib via COX-2 dependent and independent mechanisms in human gastric cancers cells. Dig Dis Sci 2009; 54: 1418-1424.
12. Lanza FL, et al,. The effects of ibuprofen, indomethacin, aspirin, naproxen, and placebo on the gastric mucosa of normal volunteers: a gastroscopic and photographic study. Dig Dis Sci 1979; 24: 823-828. (Pubitemid 10217940)
13. Patrono C,. The role of prostaglandin synthesis inhibition in the renal syndromes associated with non-narcotic analgesics. Med Toxicol 1986; 1 (Suppl. 1): 23-33. (Pubitemid 17013541)
14. Warner TD, et al,. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A 1999; 96: 7563-7568. (Pubitemid 29299702)
15. Harirforoosh S, et al,. Renal adverse effects of nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf 2009; 8: 669-681.
16. Bombardier C, et al,. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-1528.
17. Schnitzer TJ, et al,. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004; 364: 665-674. (Pubitemid 39140622)
18. Bresalier RS, et al,. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-1102. (Pubitemid 40365350)
19. Hernandez-Diaz S, et al,. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 2006; 98: 266-274.
20. McGettigan P, et al,. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296: 1633-1644. (Pubitemid 44511610)
21. Bertagnolli MM, et al,. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355: 873-884. (Pubitemid 44315980)
22. Solomon SD, et al,. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-1080. (Pubitemid 40365348)
23. Joshi GP, et al,. Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs. Anesth Analg 2007; 105: 1793-1804. (Pubitemid 350190581)
24. Capone ML, et al,. NSAIDs and cardiovascular disease: transducing human pharmacology results into clinical read-outs in the general population. Pharmacol Rep 2010; 62: 530-535.
25. Mitchell JA, et al,. Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol 1999; 128: 1121-1132.
26. Henry D, et al,. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. Br Med J 1996; 312: 1563-1566. (Pubitemid 26188573)
27. Menassé R, et al,. Pharmacological properties of diclofenac sodium and its metabolites. Scand J Rheumatol Suppl 1978; 22: 5-16. (Pubitemid 8385606)
28. Bjorkman R,. Central antinociceptive effects of non-steroidal anti-inflammatory drugs and paracetamol. Experimental studies in the rat. Acta Anaesthesiol Scand Suppl 1995; 103: 1-44.
29. Mayorek N, et al,. Diclofenac inhibits tumor growth in a murine model of pancreatic cancer by modulation of VEGF levels and arginase activity. PLoS ONE 2010; 5: e12715.
30. Bort R, et al,. Diclofenac toxicity to hepatocytes: a role for drug metabolism in cell toxicity. J Pharmacol Exp Ther 1999; 288: 65-72. (Pubitemid 29113474)
31. Hickey EJ, et al,. Diclofenac induced in vivo nephrotoxicity may involve oxidative stress-mediated massive genomic DNA fragmentation and apoptotic cell death. Free Radic Biol Med 2001; 31: 139-152. (Pubitemid 32607581)
32. Trelle S, et al,. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. Br Med J 2011; 342: c7086.
33. Gong N, et al,. The aspirin metabolite salicylate enhances neuronal excitation in rat hippocampal CA1 area through reducing GABAergic inhibition. Neuropharmacology 2008; 54: 454-463.
34. Lu YG, et al,. Salicylate, an aspirin metabolite, specifically inhibits the current mediated by glycine receptors containing alpha1-subunits. Br J Pharmacol 2009; 157: 1514-1522.
35. Peng BG, et al,. Aspirin selectively augmented N-methyl-D-aspartate types of glutamate responses in cultured spiral ganglion neurons of mice. Neurosci Lett 2003; 343: 21-24.
36. Voilley N, et al,. Nonsteroid anti-inflammatory drugs inhibit both the activity and the inflammation-induced expression of acid-sensing ion channels in nociceptors. J Neurosci 2001; 21: 8026-8033. (Pubitemid 32952759)
37. Cheng L, et al,. Niflumic acid alters gating of HCN2 pacemaker channels by interaction with the outer region of S4 voltage sensing domains. Mol Pharmacol 2009; 75: 1210-1221.
38. Zifarelli G, et al,. Identification of sites responsible for the potentiating effect of niflumic acid on ClC-Ka kidney chloride channels. Br J Pharmacol 2010; 160: 1652-1661.
39. Lee HM, et al,. Diclofenac inhibition of sodium currents in rat dorsal root ganglion neurons. Brain Res 2003; 992: 120-127. (Pubitemid 37357002)
40. + current in rat myoblasts. Biochem Biophys Res Commun 2006; 346: 1275-1283.
41. +. J Gen Physiol 2005; 125: 465-481.
42. Acosta MC, et al,. Comparative effects of the nonsteroidal anti-inflammatory drug nepafenac on corneal sensory nerve fibers responding to chemical irritation. Invest Ophthalmol Vis Sci 2007; 48: 182-188. (Pubitemid 47251401)
43. Yarishkin OV, et al,. Diclofenac, a non-steroidal anti-inflammatory drug, inhibits L-type Ca channels in neonatal rat ventricular cardiomyocytes. Korean J Physiol Pharmacol 2009; 13: 437-442.
44. Brueggemann LI, et al,. Differential effects of selective cyclooxygenase-2 inhibitors on vascular smooth muscle ion channels may account for differences in cardiovascular risk profiles. Mol Pharmacol 2009; 76: 1053-1061.
45. Villalonga N, et al,. Immunomodulatory effects of diclofenac in leukocytes through the targeting of Kv1.3 voltage-dependent potassium channels. Biochem Pharmacol 2010; 80: 858-866.
46. Peretz A, et al,. Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties. Mol Pharmacol 2005; 67: 1053-1066. (Pubitemid 40410406)
47. + current in rat cerebellar granule cells. Neuropharmacology 2005; 48: 918-926.
48. Brueggemann LI, et al,. Diclofenac distinguishes among homomeric and heteromeric potassium channels composed of KCNQ4 and KCNQ5 subunits. Mol Pharmacol 2011; 79: 10-23.
49. + channels activation. Life Sci 2004; 74: 2577-2591. (Pubitemid 38317121)
50. + channel pathway in the antinociception induced by atrial natriuretic peptide (ANP) and diclofenac. Proc West Pharmacol Soc 2002; 45: 174-177. (Pubitemid 35253085)
51. + channel pathway participates in the antinociceptive effect of diclofenac, but not of indomethacin. Pharmacol Biochem Behav 2003; 76: 187-195. (Pubitemid 38366182)
52. Ortiz MI, et al,. Additive interaction between peripheral and central mechanisms involved in the antinociceptive effect of diclofenac in the formalin test in rats. Pharmacol Biochem Behav 2008; 91: 32-37.
53. Leon-Reyes MR, et al,. Pharmacokinetic of diclofenac in the presence and absence of glibenclamide in the rat. J Pharm Pharm Sci 2009; 12: 280-287.
54. Tonussi CR, et al,. Mechanism of diclofenac analgesia: direct blockade of inflammatory sensitization. Eur J Pharmacol 1994; 251: 173-179. (Pubitemid 24061092)
55. + currents. Cell Motil Cytoskeleton 2004; 58: 127-136.
56. Dorofeeva NA, et al,. Mechanisms of non-steroid anti-inflammatory drugs action on ASICs expressed in hippocampal interneurons. J Neurochem 2008; 106: 429-441. (Pubitemid 351840226)
57. Tong J, et al,. Acid-sensing ion channels contribute to the effect of acidosis on the function of dendritic cells. J Immunol 2011; 186: 3686-3692.
58. Hu H, et al,. Activation of TRPA1 channels by fenamate nonsteroidal anti-inflammatory drugs. Pflugers Arch 2010; 459: 579-592.
59. Macianskiene R, et al,. Induction of a novel cation current in cardiac ventricular myocytes by flufenamic acid and related drugs. Br J Pharmacol 2010; 161: 416-429.
60. 2 in the regulation of programmed erythrocyte death. Cell Death Differ 2005; 12: 415-428. (Pubitemid 40662840)
61. + currents by non-metabolic and metabolic pathways in rat cerebellar granule cells. Biochem J 2011; 438: 203-215.
62. Liu Y, et al,. Inhibition of voltage-gated channel currents in rat auditory cortex neurons by salicylate. Neuropharmacology 2007; 53: 870-880. (Pubitemid 350018826)
63. Gould HJ, 3rd, et al,. Ibuprofen blocks changes in Na v 1.7 and 1.8 sodium channels associated with complete Freund's adjuvant-induced inflammation in rat. J Pain 2004; 5: 270-280.
64. 2 and CGRP within rat DRG neurons during acute incisional pain. Brain Res 2008; 1209: 57-64.
65. + current by diphenhydramine and other diphenyl compounds: molecular determinants of selective binding to the inactivated channels. Mol Pharmacol 2000; 57: 135-143.
66. McCormack K, et al,. Dissociation between the antinociceptive and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs. A survey of their analgesic efficacy. Drugs 1991; 41: 533-547. (Pubitemid 21920740)
67. Ballou LR, et al,. Nociception in cyclooxygenase isozyme-deficient mice. Proc Natl Acad Sci U S A 2000; 97: 10272-10276.
68. Butterworth JFT, et al,. Molecular mechanisms of local anesthesia: a review. Anesthesiology 1990; 72: 711-734.
69. Gwanyanya A, et al,. Magnesium-inhibited, TRPM6/7-like channel in cardiac myocytes: permeation of divalent cations and pH-mediated regulation. J Physiol 2004; 559: 761-776. (Pubitemid 39276167)
70. Liu Y, et al,. Salicylate blocks L-type calcium channels in rat inferior colliculus neurons. Hear Res 2005; 205: 271-276. (Pubitemid 40813290)
71. 2+-dependent inactivation of calcium release-activated calcium/orai channels normally prevented by mitochondria. J Biol Chem 2011; 286: 16186-16196.
72. Peretz A, et al,. A tale of switched functions: from cyclooxygenase inhibition to M-channel modulation in new diphenylamine derivatives. PLoS ONE 2007; 2: e1332.
73. + channels contribute to NSAID-inhibition of intestinal restitution. Biochem Pharmacol 2007; 74: 74-85. (Pubitemid 46802494)
74. Macias A, et al,. Celecoxib blocks cardiac Kv1.5, Kv4.3 and Kv7.1 (KCNQ1) channels: effects on cardiac action potentials. J Mol Cell Cardiol 2010; 49: 984-992.
75. Frolov RV, et al,. Inhibition of delayed rectifier potassium channels and induction of arrhythmia: a novel effect of celecoxib and the mechanism underlying it. J Biol Chem 2008; 283: 1518-1524.
76. Perianin A, et al,. Diclofenac sodium, a negative chemokinetic factor for neutrophil locomotion. Biochem Pharmacol 1985; 34: 3433-3438. (Pubitemid 16252518)
77. Martinez LL, et al,. Influence of verapamil and diclofenac on leukocyte migration in rats. Hypertension 1999; 34: 997-1001.
78. Martinez LL, et al,. Losartan attenuates the antimigratory effect of diclofenac in spontaneously hypertensive rats. J Cardiovasc Pharmacol 2005; 46: 190-199.
79. Amuzescu B, et al,. Cardiac ion channels and transporters. In:, Georgescu A, Antohe F, eds. From Vascular Cell Biology to Cardiovascular Medicine. Kerala: Transworld Research Network, 2011: 51-98.
80. + current in a vertebrate neurone. Nature 1980; 283: 673-676. (Pubitemid 10099998)
81. Takahashi Y, et al,. Muscarinic receptor type 1 (M1) stimulation, probably through KCNQ/Kv7 channel closure, increases spontaneous GABA release at the dendrodendritic synapse in the mouse accessory olfactory bulb. Brain Res 2010; 1339: 26-40.
82. V7 channels in murine vascular reactivity. Br J Pharmacol 2007; 151: 758-770. (Pubitemid 47075320)
83. Brueggemann LI, et al,. Novel actions of nonsteroidal anti-inflammatory drugs on vascular ion channels: accounting for cardiovascular side effects and identifying new therapeutic applications. Mol Cell Pharmacol 2010; 2: 15-19.
84. + channels by diclofenac. Eur J Pharmacol 2002; 438: 85-91. (Pubitemid 34242923)
85. Chai Y, et al,. Dual regulation of the ATP-sensitive potassium channel by activation of cGMP-dependent protein kinase. Pflugers Arch 2008; 456: 897-915.
86. Kawano T, et al,. Nitric oxide activates ATP-sensitive potassium channels in mammalian sensory neurons: action by direct S-nitrosylation. Mol Pain 2009; 5: e12.
87. Asomoza-Espinosa R, et al,. Sildenafil increases diclofenac antinociception in the formalin test. Eur J Pharmacol 2001; 418: 195-200. (Pubitemid 32441579)
88. Boolell M, et al,. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8: 47-52.
89. + channel pathway in the antinociceptive action of ketorolac. Eur J Pharmacol 2001; 426: 39-44.
90. 2-dependent endothelial nitric oxide synthase induction. Circ Res 2000; 87: 1149-1156.
91. Hojs N, et al,. The effect of glibenclamide on acetylcholine and sodium nitroprusside induced vasodilatation in human cutaneous microcirculation. Clin Physiol Funct Imaging 2009; 29: 38-44.
92. Lozano-Cuenca J, et al,. Peripheral and spinal mechanisms of antinociceptive action of lumiracoxib. Eur J Pharmacol 2005; 513: 81-91. (Pubitemid 40692249)
93. Ca channel osteoblast-like MG-63 cells activity in the human. J Investig Med 2001; 49: 522-533.
94. Dai L, et al,. Activation of Slo2.1 channels by niflumic acid. J Gen Physiol 2010; 135: 275-295.
95. Wang W, et al,. High doses of salicylate and aspirin are inhibitory on acid-sensing ion channels and protective against acidosis-induced neuronal injury in the rat cortical neuron. J Neurosci Res 2012; 90: 267-277.
96. Mishra V, et al,. Neuroprotective effect of flurbiprofen in focal cerebral ischemia: the possible role of ASIC1a. Neuropharmacology 2010; 59: 582-588.
97. Jones NG, et al,. Acid-induced pain and its modulation in humans. J Neurosci 2004; 24: 10974-10979. (Pubitemid 39602408)
98. Faisy C, et al,. Acid-induced modulation of airway basal tone and contractility: role of acid-sensing ion channels (ASICs) and TRPV1 receptor. Life Sci 2007; 81: 1094-1102. (Pubitemid 47418848)
99. Nilius B, et al,. Transient receptor potential cation channels in disease. Physiol Rev 2007; 87: 165-217. (Pubitemid 46207713)
100. Story GM, et al,. ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. Cell 2003; 112: 819-829. (Pubitemid 36378884)
101. Ilatovskaya DV, et al,. NSAIDs acutely inhibit TRPC channels in freshly isolated rat glomeruli. Biochem Biophys Res Commun 2011; 408: 242-247.
102. Fujimoto S, et al,. Capsaicin-induced, capsazepine-insensitive relaxation of the guinea-pig ileum. Eur J Pharmacol 2006; 530: 144-151. (Pubitemid 43037134)
103. Tajino K, et al,. Application of menthol to the skin of whole trunk in mice induces autonomic and behavioral heat-gain responses. Am J Physiol Regul Integr Comp Physiol 2007; 293: R2128-R2135. (Pubitemid 350085691)
104. Clapham DE,. SnapShot: mammalian TRP channels. Cell 2007; 129: 220.
105. Jung S, et al,. TRPC6 is a candidate channel involved in receptor-stimulated cation currents in A7r5 smooth muscle cells. Am J Physiol Cell Physiol 2002; 282: C347-C359. (Pubitemid 34663194)
106. Lang E, et al,. Enhanced eryptosis of erythrocytes from gene-targeted mice lacking annexin A7. Pflugers Arch 2010; 460: 667-676.
107. Shumilina E, et al,. Stimulation of suicidal erythrocyte death by lipoxygenase inhibitor Bay-Y5884. Cell Physiol Biochem 2006; 18: 233-242. (Pubitemid 44946978)
108. 2 dependence of the magnesium-inhibited, TRPM7-like cation channel in cardiac myocytes. Am J Physiol Cell Physiol 2006; 291: C627-C635. (Pubitemid 44497589)
109. Kozak JA, et al,. MIC channels are inhibited by internal divalent cations but not ATP. Biophys J 2003; 84: 922-927.
110. McNeill MS, et al,. Cell death of melanophores in zebrafish trpm7 mutant embryos depends on melanin synthesis. J Invest Dermatol 2007; 127: 2020-2030. (Pubitemid 47075350)
111. - secretion. J Clin Invest 1998; 102: 679-687. (Pubitemid 28399599)
112. Tondelier D, et al,. Aspirin and some other nonsteroidal anti-inflammatory drugs inhibit cystic fibrosis transmembrane conductance regulator protein gene expression in T-84 cells. Mediators Inflamm 1999; 8: 219-227. (Pubitemid 30019332)
113. Li J, et al,. Nonsteroidal anti-inflammatory drugs upregulate function of wild-type and mutant CFTR. Eur Respir J 2008; 32: 334-343.
114. Gwanyanya A, et al,. Inhibition of the calcium-activated chloride current in cardiac ventricular myocytes by N-(p-amylcinnamoyl)anthranilic acid (ACA). Biochem Biophys Res Commun 2010; 402: 531-536.
115. Yakushiji T, et al,. Non-competitive inhibition of GABAA responses by a new class of quinolones and non-steroidal anti-inflammatories in dissociated frog sensory neurones. Br J Pharmacol 1992; 105: 13-18.
116. Jett MF, et al,. Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat. J Pharmacol Exp Ther 1999; 288: 1288-1297.
117. Willis JV, et al,. The pharmacokinetics of diclofenac sodium following intravenous and oral administration. Eur J Clin Pharmacol 1979; 16: 405-410. (Pubitemid 10173752)
118. Leucuta A, et al,. No effect of short term ranitidine intake on diclofenac pharmacokinetics. Rom J Gastroenterol 2004; 13: 306-308.
119. Hunskaar S, et al,. Dissociation between antinociceptive and anti-inflammatory effects of acetylsalicylic acid and indomethacin in the formalin test. Pain 1986; 25: 125-132. (Pubitemid 16104250)
120. Cairns BE, et al,. Diclofenac exerts local anesthetic-like actions on rat masseter muscle afferent fibers. Brain Res 2008; 1194: 56-64.
121. Kearney PM, et al,. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Br Med J 2006; 332: 1302-1308.
122. Shinmura K, et al,. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci U S A 2000; 97: 10197-10202.
123. Alcindor D, et al,. Cyclooxygenase-2 mediates ischemic, anesthetic, and pharmacologic preconditioning in vivo. Anesthesiology 2004; 100: 547-554. (Pubitemid 38268871)
124. Masubuchi Y, et al,. Role of mitochondrial permeability transition in diclofenac-induced hepatocyte injury in rats. Hepatology 2002; 35: 544-551. (Pubitemid 34183957)
125. Gomez-Lechon MJ, et al,. Diclofenac induces apoptosis in hepatocytes. Toxicol In Vitro 2003; 17: 675-680.
126. 2+-dependent pore in heart mitochondria activated by inorganic phosphate and oxidative stress. Biochem J 1988; 255: 357-360.
127. Hausenloy DJ, et al,. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovasc Res 2002; 55: 534-543. (Pubitemid 34874948)
128. Sriram D, et al,. Synthesis, in vitro and in vivo antimycobacterial activities of diclofenac acid hydrazones and amides. Bioorg Med Chem 2006; 14: 3113-3118.